Brett Skinner | PhD MA BA | CEO CHPI | Editor CHP Journal

Brett Skinner is the Founder and CEO of CHPI and Editor-in-Chief of Canadian Health Policy journal (2012-present). He is an academic entrepreneur, health policy expert, and author of 2 books, over 100 major policy papers, and over 100 opinion editorials.

Dr. Skinner has a PhD from Western University, where he has lectured in the Faculty of Health Sciences and the Department of Political Science. His extensive leadership experience in policy research and advocacy includes Executive Director of Health and Economic Policy at Innovative Medicines Canada (2013-2017), and CEO (2010-2012) and Director of Health Policy (2004-2012) at Fraser Institute.

Dr. Skinner chairs CHPI’s Access to Innovative Medicines research program, an annual program of policy research designed to identify barriers to accessing new patented medicines, develop empirical metrics, and propose options for solutions.

His work has been published by think-tanks including Canadian Health Policy Institute (Toronto), Fraser Institute (Vancouver), Atlantic Institute for Market Studies (Halifax), Pacific Research Institute (San Francisco), Israel National Institute for Health Policy and Health Services Research (Tel Aviv), Galen Institute (Washington, D.C.), International Policy Network (London) and American Enterprise Institute (Washington, D.C.). His work has also been published in academic journals including Economic Affairs, Pharmacoeconomics, and Alimentary Pharmacology & Therapeutics. His opinion-editorials have been published in National Post, Financial Post, Globe and Mail, Toronto Sun, Ottawa Citizen, La Presse, Montreal Gazette, Calgary Herald, Vancouver Sun, Chicago Sun Times, and others.

Dr. Skinner appears and is cited frequently as a health policy expert in the media. He has presented his research at conferences and events in Canada, the United States, Israel and South Africa, and has testified on three occasions before the House of Commons Standing Committee on Health in Ottawa.

He is a passionate advocate for policies that promote the development of, and access to innovative medical treatments. In 2015, he was diagnosed with an atypical form of early onset Parkinson’s disease that is non-responsive to existing medications. He has both an academic interest and a personal health stake in government choices affecting future medical innovation.